The vaccine against human papillomavirus (HPV) infection appears even more effective than previously believed and protection appears to occur even when only one or two of the recommended doses are given.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
An analysis has recommended expanding HPV vaccination programs to include males in Canada because it will help protect them against HPV-related cancers.
Oncologists should raise awareness of HPV-related cancers and role of vaccinations
Teen girls living in high-poverty and in majority Hispanic communities had the highest rates of having received at least 1 dose of the HPV vaccine compared with those in low-poverty communities and in communities of other racial or ethnic compositions.
Many pediatricians and primary care physicians reported communicating about HPV vaccination with parents in ways that likely discourage them from having their children vaccinated.
Physicians failing to recommend it or adequately explain its benefits to parents could be a factor.
A sizable minority of doctors does not strongly endorse HPV vaccination nor deliver timely recommendations.
Immunization protects against sexually transmitted disease and certain cancers, health experts say, but only two U.S. states mandate vaccination.
Reports on outbreaks of measles, pertussis in past year may have shifted opinions on vaccination.
Fatalistic beliefs may affect completion of the human papillomavirus (HPV) vaccine series in some areas of the United States.
A decrease in cervical lesions among young women in the United States has been observed, but the cause for this drop is not proven.
The newest human papillomavirus (HPV) vaccine can potentially prevent 80% of cervical cancers in the United States if given to children early enough, before they are exposed to the virus.
Trial data indicates that if populations are vaccinated with Gardasil 9, approximately 90% of all cervical cancers worldwide could be prevented.
Researchers note that CDC recommends vaccination at age 11 or 12, but only half of girls receiving the vaccination get it at the proper age.
The FDA has approved Gardasil 9 for the prevention of anal, cervical, vaginal, and vulvar cancers.
Number of adolescent girls receiving the human papillomavirus (HPV) vaccine much lower in states with higher rates of cervical cancer.
Research suggests the human papillomavirus (HPV) vaccine could prevent 90 percent of cervical malignancies.
A long-term follow-up study shows the sustained efficacy, immunogenicity, and safety of GlaxoSmithKline's human papillomavirus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than 9 years, and vaccine efficacy (VE) against incident infection was 100%.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), according to a study.
The HPV vaccine protects against cancers of the cervix, throat, rectum, and penis, but too few are receiving it.
Women vaccinated with one dose of a HPV vaccine had antibodies against the viruses that remained stable in their blood for 4 years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses against new HPV infections, and ultimately cervical cancer.
HPV vaccination is widely offered but underused; many doctors continue to offer annual Pap smears.
A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women.
In 2010, 32 percent had received three doses of vaccine; incidence of some HPV-linked cancers up.
Based on the current literature associating human papillomavirus (HPV) with head and neck cancer, what public health initiatives need to be implemented?
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
What are the recommendations for administering the human papillomavirus vaccine?
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy
- Role of Oncology Nurse Navigators Has Evolved and Expanded in 5 Years
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|